Rapport Therapeutics, Inc.
RAPP
$10.05
-$0.425-4.06%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 64.18% | 111.09% | 207.31% | 167.73% | 255.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 58.58% | 58.99% | 126.27% | 213.73% | 229.30% |
| Operating Income | -58.58% | -58.99% | -126.27% | -213.73% | -229.30% |
| Income Before Tax | -6.15% | -47.86% | -101.39% | -182.74% | -268.84% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.15% | -47.79% | -101.37% | -182.65% | -268.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.15% | -47.79% | -101.37% | -182.65% | -268.78% |
| EBIT | -58.58% | -58.99% | -126.27% | -213.73% | -229.30% |
| EBITDA | -58.56% | -57.80% | -124.52% | -211.58% | -227.32% |
| EPS Basic | 93.84% | 92.88% | 91.17% | 61.84% | -145.54% |
| Normalized Basic EPS | 90.86% | 92.83% | 91.16% | 61.83% | -98.84% |
| EPS Diluted | 93.84% | 92.88% | 91.17% | 61.84% | -145.54% |
| Normalized Diluted EPS | 90.86% | 92.83% | 91.16% | 61.83% | -98.84% |
| Average Basic Shares Outstanding | 1,622.93% | 1,976.21% | 2,179.36% | 640.68% | 50.19% |
| Average Diluted Shares Outstanding | 1,622.93% | 1,976.21% | 2,179.36% | 640.68% | 50.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |